Two-Year Outcomes in the IVAN Trial
by Usha Chakravarthy, MD, FRCS, FRCOphth, PhD
Usha Chakravarthy, MD, FRCS, FRCOphth, PhD, explains the results of a 24-month trial that investigated the differences between ranibizumab and bevacizumab in terms of safety and efficacy in a fixed-dose regimen versus an as-needed regimen.
6,192 video views since 9/19/2013.
71,715 total series views.